DOP49 Efficacy of the anti-mucosal addressin cell adhesion molecule-1 (MAdCAM-1) antibody SHP647 in ulcerative colitis: results from the open-label extension study TURANDOT II

Reinisch, Walter; Sandborn, William J.; Danese, Silvio; Hébuterne, Xavier; Kłopocka, Maria; Tarabar, Dino; Vanasek, Thomas; Greguš, Miloš; Hellstern, Paul; Kim, J S; Sparrow, Miles P.; Gorelick, Ken; Goetsch, Martina; Bliss, Caleb; Gupta, Charu; Cataldi, Fabio; Vermeire, Séverine

doi:10.1093/ecco-jcc/jjy222.083

Cited by 4 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the phase 1 safety study, TOSCA, in patients with active CD, 12 weeks of SHP647/ontamalimab induction therapy did not result in a reduction in CSF lymphocytes or T‐cell subsets or CD4:CD8 ratio . The data from extension studies for UC (TURNADOT II) and CD (OPERA and TOSCA) demonstrated that efficacy achieved with SHP647/ontamalimab induction were maintained for up to 144 weeks and 72 weeks, respectively . Although SHP647/ontamalimab demonstrated a favorable safety profile in both UC and CD, its efficacy was less robust for CD, highlighting the complexity of the mechanisms underlying IBD as well as the therapeutic challenges.…”

Section: A Model For Integrins and T Lymphocytes As Therapeutic Targementioning

confidence: 99%

The role of integrins in the pathogenesis of inflammatory bowel disease: Approved and investigational anti‐integrin therapies

Dotan

Allez

Danese

et al. 2019

Medicinal Research Reviews

View full text Add to dashboard Cite

Inflammatory bowel disease (IBD) is characterized by uncontrolled inflammation in the gastrointestinal tract. The underlying pathobiology of IBD includes an increase in infiltrating gut‐homing lymphocytes. Although lymphocyte homing is typically a tightly regulated and stepwise process involving multiple integrins and adhesion molecules expressed on endothelial cells, the distinct roles of integrin‐expressing immune cells is not fully understood in the pathology of IBD. In this review, we detail the involvement of integrins expressed on specific lymphocyte subsets in the pathogenesis of IBD and discuss the current status of approved and investigational integrin‐targeted therapies.

show abstract

Section: A Model For Integrins and T Lymphocytes As Therapeutic Targementioning

confidence: 99%